Comment on Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659

Key Points

• The main aim is to evaluate the potential of clinically approved therapies for treating medulloblastoma.
• Critically assess existing clinical trials involving medulloblastoma treatments.
• Identify opportunities for repositioning established drugs.
• Analyze the mechanism of action of these therapies in the context of medulloblastoma.
• Several approved therapies show promise in improving medulloblastoma treatment outcomes.
• Repositioning strategies may enhance drug efficacy and reduce side effects.
• Potential to expedite treatment availability for patients through existing therapies.